XILIO THERAPEUTICS INC
XLONASDAQTrading Snapshot
- Day Range
- $702.58 – $723.70
- 52-Week Range
- $6.47 – $12.74
- Volume
- $2.15B
- Avg Volume
- $1.77B
- Shares Outstanding
- 6.0M
- Next Earnings
- Sep 26, 2026
Fundamentals Snapshot
- Annual Revenue
- $44M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- 1.0x
- EPS (TTM)
- $-3.51
- Dividend Yield
- —
Why Investors Own XLO
- ✓High-growth profile — revenue up +39.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 18% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About XILIO THERAPEUTICS INC
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
